Epitopea has appointed Dr. Lisa Butterfield to its Scientific Advisory Board, enhancing its leadership in the development of RNA-based immunotherapies for solid tumors. Dr. Butterfield, a prominent figure in immuno-oncology with extensive experience in cancer vaccines and cellular therapies, will play a crucial role as Epitopea advances its lead candidate, CryptiVax™-1001, targeting high-grade serous ovarian cancer. Her prior positions include significant roles at Merck and the Parker Institute for Cancer Immunotherapy, along with academic leadership at the University of Pittsburgh.

The significance of Dr. Butterfield’s appointment lies in her expertise in tumor-specific antigens (TSAs) and immune profiling, which are pivotal for the success of Epitopea’s innovative approach. The company’s proprietary CryptoMap™ platform identifies aberrantly expressed antigens from previously uncharacterized genomic regions, facilitating the development of off-the-shelf mRNA vaccines designed to elicit robust immune responses across diverse patient populations. This is particularly critical given the limited treatment options available for patients with advanced cancers, where durable therapeutic responses are often elusive.

The key takeaway from this development is the potential shift in the landscape of cancer immunotherapy that Epitopea aims to achieve. By leveraging Dr. Butterfield’s insights and the company’s novel antigen discovery methods, Epitopea is positioned to accelerate the translation of its findings into clinically viable therapies. This could significantly shorten drug development timelines and enhance the accessibility of effective treatments for hard-to-treat solid tumors, ultimately addressing a major unmet need in oncology.

Source: globenewswire.com